628 related articles for article (PubMed ID: 29459281)
1. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
6. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
8. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preclinical evaluation of an Al
Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
[TBL] [Abstract][Full Text] [Related]
11. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
[TBL] [Abstract][Full Text] [Related]
12. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
13. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
14. Radiochemistry and Preclinical PET Imaging of
Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
[TBL] [Abstract][Full Text] [Related]
15. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
Baranski AC; Schäfer M; Bauder-Wüst U; Roscher M; Schmidt J; Stenau E; Simpfendörfer T; Teber D; Maier-Hein L; Hadaschik B; Haberkorn U; Eder M; Kopka K
J Nucl Med; 2018 Apr; 59(4):639-645. PubMed ID: 29191856
[TBL] [Abstract][Full Text] [Related]
16. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
[TBL] [Abstract][Full Text] [Related]
17. Effects of Linker Modification on Tumor-to-Kidney Contrast of
Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
[No Abstract] [Full Text] [Related]
18.
Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
20. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]